Figure 7

Immunohistochemistry of inflammation markers in a cohort of 123 patients with GBM tumors.

(a) Number of negative and positive immuno-labeled samples for LysM, CD11c, Iba1 and CD11b inflammation markers. Overall survival (OS) and progression free survival (PFS) were calculated for negative and positive groups for each marker and were compared using the log-rank test (p-value). N.S.: not significant. (b) Representative LysM distribution in GBM tumor. LysM staining was denser in the core (T, top) than in the periphery of the tumor (P, bottom). (c) Representative CD11c distribution in GBM tumor. CD11c staining was denser in the core (T, top) than in the periphery of the tumor (P, bottom). (d) Representative picture of LysM labeling with positivity in the tumor core (top) and inside vessels (bottom). (e) CD11c⁺ cell morphologies: round (top); star-shaped (bottom) (f ) Representative pictures of Iba1⁺ cell morphologies: round (right) and star shaped (left). Scale-bars: 50 μm.